MicroRNAs 146a/b-5p, 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes



Background: Antidepressants (ADs) are the most common treatment for major depressive disorder (MDD). However, only about 30% of patients experience adequate response after a single AD trial, and this variability remains poorly understood. Here, we investigated microRNAs (miRNAs) as biomarkers of AD response using small RNA-sequencing in paired samples from MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before and eight weeks after treatment.; Results: Our results revealed differential expression of miR-146a-5p, miR-146b-5p, miR-425-3p and miR-24-3p according to treatment response. These results were replicated in two independent clinical trials of MDD, a well-characterized animal model of depression, and post-mortem human brains. Furthermore, using a combination of bioinformatics, mRNA studies and functional in vitro experiments, we showed significant dysregulation of genes involved in MAPK/Wnt signaling pathways.; Conclusions: Together, our results indicate that these miRNAs are consistent markers of treatment response and regulators of the MAPK/Wnt systems.

Overall Design

MicroRNAs as biomarkers of antidepressant response


Data and Resources

Raw Files [445]

Additional Info

Field Value
Source https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97154
Type of Data

Non-coding RNA profiling by high throughput sequencing


RNA Sequencing

GSE Submission Date 28/03/2017
GSE Authors Juan,P,Lopez; Gustavo Turecki; Jean-François Théroux
Dataset Last Updated December 7, 2020, 12:11 (UTC)
Dataset Created December 7, 2020, 11:31 (UTC)